Two events in the last decade have set the stage for the large-scale clinical testing of
chemopreventive agents for colorectal cancer in people at low to moderate risk for this …

Population-based studies have established that long-term intake of non-steroidal anti-
inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of …

Use of nonsteroidal anti‐inflammatory drugs such as aspirin, which are known to inhibit
cyclooxygenase activity, reduces the relative risk of colorectal cancer in humans by 40–50 …

The limited success of current treatments for most advanced common malignancies
highlights the importance of cancer prevention. Clinical trials on cyclooxygenase (COX) …

Inhibitors of the inducible cyclooxygenase (COX‐2) have emerged as a promising new class
of drugs that may be useful for the prevention of colorectal cancer. Experimental evidence to …

Colorectal cancer (CRC) leads to approximately 550,000 annual deaths worldwide and is
thus a major public health concern [1]. Once an individual is diagnosed with CRC, the …

Abstract Cyclooxygenase‐2 (COX‐2) is an inducible enzyme that regulates prostaglandin
synthesis and is overexpressed at sites of inflammation and in several epithelial cancers. A …

Abstract Cyclooxygenase-2 (COX-2) is an inducible enzyme that regulates prostaglandin
synthesis and is overexpressed at sites of inflammation and in several epithelial cancers …

Abstract Cyclooxygenase 2 (COX-2), also called prostaglandin endoperoxide synthase 2, is
involved in colorectal tumor development. This review deals with particular questions raised …

Background Cyclo-oxygenase inhibition for the treatment of colorectal neoplasia has been
studied with renewed interest since the discovery of cyclo-oxygenase (Cox) 2 and the …